Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 16;38(25):2916–2925. doi: 10.1200/JCO.19.03054

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 2. — Effects of pembrolizumab monotherapy in patients with recurrent and/or metastatic cutaneous squamous cell carcinoma (cSCC). (A) An 80-year-old man with cSCC at the temple who previously underwent surgery at baseline (left), after 6 weeks of treatment (middle), and at the most recent follow-up (35 weeks; right). (B) An 87-year-old woman with cSCC at the jaw who previously received systemic therapy and radiation at baseline (left), after 6 weeks of treatment (middle), and at the most recent follow-up (37 weeks; right). (C) An 84-year-old woman with cSCC at the right axilla who previously underwent surgery and radiation at baseline (left), after 6 weeks of treatment (middle), and at the most recent follow-up (36 weeks; right). (D) A 92-year-old man with cSCC at the ear who previously received systemic therapy at baseline (left), after 6 weeks of treatment (middle), and at the most recent follow-up (62 weeks; right). Weeks are time since the date of the first dose of pembrolizumab.

FIG 2. — Effects of pembrolizumab monotherapy in patients with recurrent and/or metastatic cutaneous squamous cell carcinoma (cSCC). (A) An 80-year-old man with cSCC at the temple who previously underwent surgery at baseline (left), after 6 weeks of treatment (middle), and at the most recent follow-up (35 weeks; right). (B) An 87-year-old woman with cSCC at the jaw who previously received systemic therapy and radiation at baseline (left), after 6 weeks of treatment (middle), and at the most recent follow-up (37 weeks; right). (C) An 84-year-old woman with cSCC at the right axilla who previously underwent surgery and radiation at baseline (left), after 6 weeks of treatment (middle), and at the most recent follow-up (36 weeks; right). (D) A 92-year-old man with cSCC at the ear who previously received systemic therapy at baseline (left), after 6 weeks of treatment (middle), and at the most recent follow-up (62 weeks; right). Weeks are time since the date of the first dose of pembrolizumab.